News
JPMorgan Chase will increase its dividend by 7%, well above the 3% projection, after banks sailed through the Fed’s annual ...
Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID ...
Goldman Sachs on Wednesday named Raghav Maliah chairman of investment banking, a global position in addition to the banker's ...
Hosted on MSN5mon
Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares fell 2% in ...
The S&P 500 and Nasdaq added to their all-time highs at midday as investors anticipated more U.S. trade agreements ahead.
12don MSN
Goldman Sachs updated its Sharpe Ratio basket, a list of 50 stocks with the highest expected risk-adjusted returns in the ...
Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.
Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) shares fell 2.2% Thursday as the company confirmed it is seeking outside investment to support its late-stage vaccine programs. The move underscores the biotech ...
Goldman Sachs analyst Salveen Richter downgrades Moderna from Buy to Neutral and lowers the price target from $99 to $51. The analyst expects Moderna to report product revenue at the low end of ...
Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...
Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (WBAG:MRNA) from Buy to Neutral. There are 1,449 funds or institutions reporting positions in Moderna ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results